



*Empowered lives.
Resilient nations.*

Research outcomes as Global Public Goods


Tenu Avafia
HIV, Health and Development Group
UNDP




UNSG's High-level panel on Access to Medicines



Empowered lives.
Resilient nations.



Research Outcomes as Global Public Goods



- UN Member States must increase public investments in R&D for TB & other unmet health needs
- Universities, research institutions must prioritize public health objectives in patent & licensing practices
- HLP reiterated importance of norms and principles to guide R&D for unmet health needs such as TB to ensure return on investments and equitable access
- Language dates back to WHO CEWG, and endorsed by UN Member states at 2016 HLM on AMR

Language on R&D in HLM on AMR

- *all research and development efforts should be needs-driven, evidence-based and guided by the principles of affordability, effectiveness and efficiency and equity, and should be considered as a shared responsibility. In this regard, we acknowledge the importance of delinking the cost of investment in research and development on antimicrobial resistance from the price and volume of sales*

Transparency as an enabler of global public goods



- Governments should require all manufacturers and distributors to disclose to drug regulators and procurers the costs of:
 - R&D; production; marketing and distribution
 - Any public funding received in the development of health technologies e.g. tax credits, subsidies & grants
- Governments should require that data on all completed and discontinued clinical trials be made publicly available regardless of outcome
- Leadership on open access coming from Wellcome trust & BMGF